Profil
Paul McInulty is currently the Senior Vice President-Regulatory Affairs at Arvinas, Inc. Prior to this, he worked as the Vice President-Therapeutic Head & Hematology at Bristol Myers Squibb Co. and as the Vice President-Regulatory Affairs at Celgene Corp.
He completed his undergraduate degree at The University of Sheffield.
Aktive Positionen von Paul McInulty
| Unternehmen | Position | Beginn |
|---|---|---|
| ARVINAS, INC. | General Counsel | 03.10.2022 |
Ehemalige bekannte Positionen von Paul McInulty
| Unternehmen | Position | Ende |
|---|---|---|
| CELGENE | General Counsel | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Ausbildung von Paul McInulty
| The University of Sheffield | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ARVINAS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
